MOH INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Molina Healthcare, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

(NYSE:MOH), SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Molina Healthcare, Inc. (NYSE: MOH) securities between February 5, 2025 and July 23, 2025, both dates inclusive (the “Class Period”), have until Tuesday, December 2, 2025 to seek appointment as […]

Floating Solar Panels Market Growing at 26%+ CAGR to 2030 Driven by Renewable Energy Demand, Reports Mordor Intelligence

According to the latest insights from Mordor Intelligence, the floating solar panels market size is projected to grow from USD 1.06 billion in 2025 to USD 3.39 billion by 2030. This growth is driven by limited land availability, increasing utility decarbonization targets, and enhanced energy efficiency from water-based cooling. https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg The Asia-Pacific region leads the

MOH INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Molina Healthcare, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

MOH INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Molina Healthcare, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit GlobeNewswire October 21, 2025 SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Molina

Maison&Objet Intérieurs Hong Kong Unveils Full Programme: Design Factory, Design Showcase & Le Club

3-6 December 2025 at HKCEC: Eight immersive interiors, a special Mobilier National presentation, 200+ brands and a curated business lounge Maison&Objet Intérieurs Hong Kong returns 3-6 December 2025 to the Hong Kong Convention and Exhibition Centre (HKCEC) with three core sections – Design Factory, Design Showcase and Le Club – under the theme “Crossroads,” spotlighting

Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

Nine funds are single-stock leveraged ETFs seeking 200% long exposure Tradr ETFs,a provider of ETFs designed for sophisticated investors and professional traders, announced that it expects to launch nine new single stock leveraged ETFs on Thursday, October 23. The funds will be listed on Cboe, and each ETF aims to deliver twice (200%) the daily

Unitil Schedules Third Quarter 2025 Earnings Release and Conference Call

(NYSE:UTL), HAMPTON, N.H., Oct. 21, 2025 (GLOBE NEWSWIRE) — Unitil Corporation (NYSE: UTL) (unitil.com) has scheduled the release of its third quarter 2025 earnings after the market closes on November 3, 2025. Unitil will host its conference call and webcast on November 4, 2025 at 2:00 p.m. (ET) to review its quarterly results. Related presentation

Miami International Holdings Announces Date of Third Quarter 2025 Earnings Release and Conference Call

Miami International Holdings, Inc. (NYSE: MIAX), a technology-driven leader in building and operating regulated financial markets across multiple asset classes, will release its financial results for the third quarter ended September 30, 2025 after the close of market trading on Wednesday, November 5, 2025. A conference call with remarks by the company's senior management will

Correction: Physitrack PLC – Interim Report: January – September 2025

The Wellness revenue table has been updated to reflect accurate figures for Q3 2025. No impact to Group consolidated results or commentary. LONDON, GB / ACCESS Newswire / October 21, 2025 / Physitrack PLC (STO:PTRK) – Fourth Consecutive Quarter of Resilient, Cash-Generative Growth, Marking Historical Positive Cash flow. Investor snapshot Metric Q3 2025 Q3 2024

IASO Bio Announces Approval of Clinical Trial Notification for its BCMA CAR-T Product in Japan

IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announcedthe Clinical Trial Notification (CTN) for its independently developed fully human anti-BCMA CAR-T cell therapy was approved in Japan. The approval of the CTN in Japan for this product indicates that Japanese regulatory authorities have

Scroll to Top